Released: March 10, 2023
Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Pancreatic Cancer Research Program
Anticipated Funding Opportunities for Fiscal Year 2023 (FY23)
The FY23 Defense Appropriations Act provides funding for the Pancreatic Cancer Research Program (PCARP) to support research of exceptional scientific merit and innovation with high impact that focuses on pancreatic cancer. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).
The PCARP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY23 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY23 PCARP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.
Applications submitted to the FY23 PCARP must address one or more of the following Focus Areas:
- Early detection research for pancreatic cancer, including the prevalence in individuals with pre-diabetes and diabetes and/or those in underserved ethnic and minority communities
- Supportive care interventions, patient-reported outcomes, quality of life, and perspectives during diagnosis, treatment, and survivorship
- Barriers to the implementation of health care, including ways to overcome socioeconomic, geographic, or ethnic and racial disparities
- Identification and characterization of pancreatic cancer risk including genetic and environmental risk factors, such as diet, obesity, and microbiome
- Understanding the relationship between metabolic disruptions in pancreatic cancer and their systemic effects, including diabetes and cachexia
- Understanding tumor development and progression, from precursors to metastasis
- Understanding the relationship between oncogenic signaling and the tumor microenvironment that drives drug resistance and therapeutic response
- Biomarkers to predict therapeutic response and guide management strategies
- New drug development targeted toward cancer sensitivity and resistance mechanisms including immune mechanisms of resistance
|Award Mechanism||Eligibility||Key Mechanism Elements||Funding|
|Idea Development Award||
Investigators at or above the level of Assistant Professor (or equivalent)
Early-Career Investigator Partnering Principal Investigator (PI) Option:Investigators at or above the level of Assistant Professor (or equivalent) may collaborate on a single application with an early-career investigator that meets the following criteria at the application submission deadline date:
Early-Career Investigator Partnering PI Option supports applicants early in their faculty appointments or in the process of developing independent research careers.
Early-Career Investigator Partnering PI Option:
|Translational Research Partnership Award||
PIs must be at or above the level of Assistant Professor or equivalent.
Clinicians must be an M.D., M.D./Ph.D., or equivalent with clinical duties and/or responsibilities.
Postdoctoral and clinical fellows are not eligible.
At least one member of the partnership must have expertise either in pancreatic cancer research or pancreatic cancer patient care.
|Focused Pilot Award
(New for FY23!)
Applications can include investigators at all academic levels.
Postdoctoral and clinical fellows are eligible.
A pre-application is required and must be submitted through the Biomedical Research Application Portal (eBRAP) prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using Assistance Listing Number (ALN, formerly CFDA) 12.420.
Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage. For more information about the PCARP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).
Point of Contact:
CDMRP Public Affairs
Last updated Friday, March 10, 2023